CoChat

Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: Randomized, double‐blind, placebo‐controlled study

Open access
Emamzadehfard, Sahra, Kamaloo, Atefeh, Paydary, Koosha, Ahmadipour, Ahmad, Zeinoddini, Arefeh, Ghaleiha, Ali, Mohammadinejad, Payam, Zeinoddini, Atefeh, Akhondzadeh, Shahin · 2016 · Psychiatry and Clinical Neurosciences
Cited by 55

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Aim: The aim of the present randomized, double‐blind, placebo‐controlled, 8‐week trial was to assess the efficacy and tolerability of riluzole augmentation of fluvoxamine in treatment of patients with moderate to severe obsessive–compulsive disorder. Methods: Patients were randomized into two parallel groups to receive fluvoxamine plus placebo or fluvoxamine plus riluzole (50 mg twice daily). All patients, regardless of their treatment group, received fluvoxamine at 100 mg/day for the initial 4 weeks of the study followed by 200 mg/day of fluvoxamine for the rest of the trial course. A total of 50 patients (25 in each group) were evaluated for response to treatment using the Yale–B rown O bsessive C ompulsive S cale (Y‐BOCS) at baseline and at weeks 4, 8 and 10. Side‐effects were recorded using predesigned checklists in each visit. Repeated‐measure analysis of variance showed a significant effect for time × treatment interaction in the Y‐BOCS total score and a significant effect for time × treatment interaction in the Y‐BOCS Compulsive subscale score between the two groups. Results: Repeated‐measure analysis of variance showed a significant effect for time × treatment interaction (Greenhouse–G eisser corrected: F = 4.07, d.f. = 1.22, P = 0.04) in the Y‐BOCS total score and a significant effect for time × treatment interaction (Greenhouse–G eisser corrected: F = 4.45, d.f. = 1.33, P = 0.028) in the Y‐BOCS Compulsive subscale score between the two groups. Riluzole augmentation therapy demonstrated higher, partial or complete treatment response according to the Y‐BOCS total scores. Conclusion: Riluzole may be of clinical use as an adjuvant agent to fluvoxamine in treatment of moderate to severe obsessive–compulsive disorder.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/pcn.12394

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

Metadata

Authors
Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S.
Venue
Psychiatry and Clinical Neurosciences
Publisher
Wiley
Published
2016-05-26
Volume
70
Issue
8
Pages
332-341
ISSN
  • 1323-1316 (ISSN-L)
  • 1440-1819
OpenAlex
W2341125861
Cited by
55
References
21
FWCI
8.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.